Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
NXTC — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

48.67

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.04

EPS Last/This Y

12.19

EPS This/Next Y

0.4

Price

5.88

Target Price

20

Analyst Recom

1

Performance Q

-42.63

Upside

-11,528.9%

Beta

1.32

Ticker: NXTC




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13NXTC2.2N/AN/A0
2026-07-14NXTC6.41N/AN/A0
2026-07-15NXTC6.57N/AN/A0
2026-07-16NXTC6.295N/AN/A0
2026-07-17NXTC5.98N/AN/A0
2026-07-20NXTC5.41N/AN/A0
2026-07-21NXTC5.12N/AN/A0
2026-07-22NXTC4.41N/AN/A0
2026-07-23NXTC4.18N/AN/A0
2026-07-24NXTC4.25N/AN/A0
2026-07-27NXTC5.13N/AN/A0
2026-07-28NXTC5.43N/AN/A0
2026-07-29NXTC5.02N/AN/A0
2026-07-30NXTC5N/AN/A0
2026-07-31NXTC4.14N/AN/A0
2026-08-03NXTC4.28N/AN/A0
2026-08-04NXTC5.83N/AN/A0
2026-08-05NXTC5.27N/AN/A0
2026-08-07NXTC5.91N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13NXTC2.1883.0- -7.32
2026-07-14NXTC6.4583.0- -7.32
2026-07-15NXTC6.5683.0- -7.32
2026-07-16NXTC6.2883.0- -7.32
2026-07-17NXTC6.0083.0- -7.46
2026-07-20NXTC5.4583.0- -7.46
2026-07-21NXTC5.1283.0- -7.46
2026-07-22NXTC4.4083.0- -7.46
2026-07-23NXTC4.1983.0- -7.46
2026-07-24NXTC4.2483.0- -7.46
2026-07-27NXTC5.1383.0- -7.46
2026-07-28NXTC5.4783.0- -7.46
2026-07-29NXTC5.0583.0- -7.46
2026-07-30NXTC5.0583.0- -7.46
2026-07-31NXTC4.1083.0- -7.46
2026-08-03NXTC4.4083.0- -7.46
2026-08-04NXTC4.4083.0- -7.46
2026-08-05NXTC5.2883.0- -7.46
2026-08-06NXTC5.5283.0- -7.46
2026-08-07NXTC5.8883.0- -7.46
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13NXTC0.007.396.69
2026-07-14NXTC0.007.396.69
2026-07-15NXTC0.007.396.69
2026-07-16NXTC0.007.396.69
2026-07-17NXTC0.007.396.69
2026-07-20NXTC0.006.515.94
2026-07-21NXTC0.006.515.94
2026-07-22NXTC0.006.515.94
2026-07-23NXTC0.006.515.94
2026-07-24NXTC0.006.515.94
2026-07-27NXTC0.006.5149.58
2026-07-28NXTC0.006.5149.58
2026-07-29NXTC0.006.5149.58
2026-07-30NXTC1.286.5149.58
2026-07-31NXTC1.286.5149.58
2026-08-03NXTC1.286.5149.58
2026-08-04NXTC33.076.5148.67
2026-08-05NXTC34.736.5148.67
2026-08-06NXTC34.716.5148.67
2026-08-07NXTC34.726.5148.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.87

Avg. EPS Est. Current Quarter

-1.92

Avg. EPS Est. Next Quarter

-1.83

Insider Transactions

34.72

Institutional Transactions

6.51

Beta

1.32

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

19

Sentiment Score

91

Actual DrawDown %

94.7

Max Drawdown 5-Year %

-98.5

Target Price

20

P/E

Forward P/E

PEG

P/S

P/B

0.79

P/Free Cash Flow

EPS

-19.07

Average EPS Est. Cur. Y​

-7.46

EPS Next Y. (Est.)

-7.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.12

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.14

EBIT Estimation

NXTC Healthcare
$5.84
📉
Swing / Pullback
Buy the dip on strong trends
37 /100
WEAK
Trend
4/20
Pullback
6/25
Volume
11/15
Valuation
12/20
TP/AR
4/10
Options
0/10
RSI
59.8
Range 1M
48.3%
Sup Dist
12.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
31 /100
WEAK
Momentum
3/25
Growth
20/30
Estimates
2/20
Inst/Vol
6/15
Options
0/10
EPS Yr
62.4%
EPS NY
19.5%
52W%
28.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +242.5% upside
Quality
2/30
Valuation
16/30
Growth
14/25
Stability
8/10
LT Trend
2/5
Upside
+242.5%
Quality
3
NXTC — P/E HistoricalBiotechnology
NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 40
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC

Latest News

Caricamento notizie per NXTC
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading